PUBLIC COMPANY
save$XENEXenon Pharmaceuticals Inc.
$XENE38.02-2.34%Burnaby, British Columbia, Canadaupdated 1d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
- phase3A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
- phase3An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
- phase3An Open-label Study of XEN1101 in Epilepsy
- phase3A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
- phase3An Open-Label Study of Azetukalner in Major Depressive Disorder
- phase3A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
- phase3A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
🐶 Hiring Signal
News
- Xenon shares fall following depression trial pauseThe occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.biopharma_dive · 16d ago
- Xenon tumbles on voluntary psychiatry hold, but analysts confident in $2B epilepsy opportunityAs Xenon Pharmaceuticals announced that azetukalner has reached the FDA for focal seizures, the company also disclosed the emergence of psychosis adverse events in psychiatric trials of the drug, t…biospace · 16d ago
- Xenon pauses phase 3 depression trials after psychosis eventsThe company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate adverse events.fiercebiotech · 17d ago
- SK Biopharma pens $795M deal to usher Biohaven’s epilepsy therapy towards hoped-for 2029 launchSK Biopharmaceuticals has strengthened its epilepsy offering by paying $350 million upfront to help speed Biohaven’s Kv7 ion channel activator on its way to market.fiercebiotech · 1mo ago
- NewLimit’s $435M megaround; Lilly’s busy dealmaking weekThe anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.biopharma_dive · 4mo ago
- A year after Vertex’s big launch, pain drug research faces a pivotal momentJournavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?biopharma_dive · 4mo ago
Data sources
last refreshed 20m ago
Found something off?
comments(0)
5-min edit window · permanent after that